# Rhizome AI -- Sam Lessin Evaluation

Here's the thing that jumps out immediately: Clarivate has already shipped an AI-powered Regulatory Assistant inside Cortellis, the platform used by literally 100% of the top-20 pharma companies. This isn't a hypothetical incumbent response — it's a present-tense competitive reality. When I see a startup building "AI-powered Q&A for [regulated vertical]" and the dominant incumbent has already bolted the same capability onto its existing distribution, I don't need to run the rest of my analysis to know the structural position is weak. But let me run it anyway, because the founder's execution here deserves a genuine look.

Chetan Mishra is credible. Employee #16 at Instabase, where he built document processing systems for banks — directly relevant to extracting structured intelligence from massive regulatory corpora. Sole founding product engineer at EvolutionaryScale, which pulled in $142M from Amazon and Nvidia. He's seen scale, he's shipped product in regulated contexts, and he identified a real gap: most AI in life sciences focuses on drug discovery, not on the messy regulatory work of actually bringing drugs to market. That observation is sharp. But "sane person, sane idea" is the least interesting quadrant in my framework. Building an AI tool to answer regulatory questions from public FDA and EMA databases is exactly what every LLM-aware person in life sciences thought of the moment GPT-4 shipped. There's nothing non-consensus here. The idea doesn't provoke skepticism — it provokes a nod.

My "cherry on top" test kills this one cleanly. Would Rhizome be a good business if AI didn't exist? No. Without the AI layer, this is a document search interface competing with Clarivate's decades-old structured databases across 80+ markets. The AI isn't a cherry on top of a fundamentally strong business — the AI IS the business. The 2.5TB corpus is assembled from public regulatory databases that any funded competitor can access. The zero-hallucination claim across 2,800+ questions in 2025 is impressive engineering, but it's a quality benchmark, not a structural moat. Quality benchmarks get matched; they don't compound. Clarivate can throw resources at retrieval accuracy from inside its installed base. Freyr has 2,300 regulatory consultants who can validate and improve an AI tool with domain knowledge Rhizome's solo founder simply cannot replicate at scale.

The bull case deserves honest engagement: regulated industries create trust moats that look invisible in competitive analysis. Once a regulatory affairs team at Pfizer relies on Rhizome's answers to inform an FDA submission, the cost of switching to a tool that might hallucinate even once is measured in billions of dollars of drug approval delays. That trust premium is real, and Chetan's execution — six figures in revenue with 20+ customers as a solo founder selling into pharma — suggests he's found something that works in practice even if the structural logic looks fragile in theory. If Clarivate's AI bolt-on turns out to be mediocre (incumbents are usually bad at this), and if Rhizome can establish itself as the trusted answer engine before anyone else achieves comparable accuracy, there's a narrow path to a meaningful business. The pricing tiers — from $400/month self-serve to custom enterprise — show smart distribution thinking, letting individual regulatory professionals adopt bottom-up before expanding to team licenses.

But narrow paths to meaningful businesses aren't what I invest in. I'm looking for infinity stories with structural moats, and this is a bounded story with a software moat. The regulatory affairs market is real but capped — "always know what the FDA thinks" doesn't elastically expand into new economic categories the way Helium expanded from IoT hotspots to decentralized wireless infrastructure. The company creates no new primitive that others build on; no one's product improves because Rhizome exists. It's an application-layer tool on top of public data and general-purpose LLM infrastructure, competing in a market where the incumbent already has distribution to every target customer. I'd rather invest in a company building regulatory submission infrastructure — the actual pipeline that drugs flow through — than an intelligence layer that reads public documents more efficiently. This is a feature that a well-resourced team at Clarivate, or frankly at any of the foundation model companies, can replicate once the market proves out. Chetan is executing impressively, but impressive execution of a structurally vulnerable idea is how you end up with Birchbox outcomes.

### Dimension Scores

| Criterion | Score |
|-----------|-------|
| "Sane Person, Insane Idea" Calibration | 10/30 |
| AI-Resistant Structural Moat | 5/25 |
| New Primitive or Protocol Position | 4/20 |
| Narrative Magnitude and Infinity Optionality | 6/15 |
| Real Revenue or Asset Cushion | 7/10 |
| **Total** | **32/100** |

**Total Score: 32/100** (Pass)
